Horn Howard sold $111K of RARE

Horn Howard (Chief Financial Officer) sold 4,653 shares of Ultragenyx Pharmaceutical Inc. (RARE) at $23.77 ($0.11M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Horn Howard
Published Jun 1, 2026, 11:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 1, 2026, 11:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RARE
Neutral
high confidence
Mentioned
$RARE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RARENeutralLow
01

Why it matters

The disclosed sale is a mechanical disclosure rather than a fundamental update; absent other catalysts, it is unlikely to change valuation drivers.

02

Market read

Insider selling disclosure for RARE with limited incremental trading signal due to 10b5-1 pre-arrangement and lack of new business information.

03

What to watch

The filing does not reveal the broader context (e.g., total insider activity over prior months, tax-related selling, or diversification needs).

Relevance 6/10Novelty 3/10Timing: Filed today (2026-06-01) for an insider sale executed the same day.

Background

SEC Form 4 reports insider transactions; this one is an officer/direct sale under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$RARENeutralHigh confidence
Context

Ultragenyx CFO Horn Howard sold 4,653 shares in an open-market transaction at $23.77 on a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any reaction would be muted unless paired with other company-specific news.

Evidence & confidence

Form 4 insider sales are typically informational but not necessarily bearish, especially when explicitly executed under a pre-arranged 10b5-1 plan and without accompanying guidance/trial/contract updates.

Market effects

Minimal; single-company Form 4 insider sale does not reset sector expectations.

None indicated.

None indicated.

Counterpoint

Even 10b5-1 sales can coincide with management confidence gaps; traders may still interpret repeated insider selling as a risk signal if it accelerates.

Key entities

  • Horn Howard

    Ultragenyx CFO who sold 4,653 shares under a pre-arranged 10b5-1 plan.

  • Ultragenyx Pharmaceutical Inc.

    RARE, the company whose shares were sold by its CFO.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RAREMed

Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy

Ultragenyx Pharmaceutical Inc (RARE) discontinued two gene therapy programs (GTX-102 and UX701) due to efficacy and trial advancement issues. The company is restructuring, cutting 20% of its workforce. The future of setrusumab for osteogenesis imperfecta is uncertain pending FDA discussions. R&D spending for 2027 is guided at less than $350 million, with a focus on commercial products. The company faces potential competition in the Sanfilippo syndrome type A market.

$RAREHighAI 8/10

Ultragenyx (RARE) Q3 2026 Earnings Call Transcript

Ultragenyx (RARE) reported Q3 2026 earnings, highlighting FDA approvals for GENGLYCOS and FAYUVI, two new gene therapies. The company also announced setbacks in clinical trials for GTX-102 and UX701, leading to program terminations and workforce reductions. Revenue guidance for 2026 was reaffirmed at $730M-$760M, with profitability expected in 2027. The company aims to reduce expenses by 50% by 2027.